Strat Petroleum Ltd (SPRL): If it does not go lower, it will be the...

slice8 · 2007-03-08T13:20:07.8730000Z

If it does not go lower, it will be the first time out of about 400 times where I thought it couldn't go lower and yet did... The afterhours trade of 940,000 shares is another indication that the dilution continies. There is no reason to believe that it will stop on any given day. If anything, it may increase as more shares are needed issued to raise the same amount of capital. If Sam had any real news, he would have released it by now; price would rise and he could issue fewer shares. News will come when there is news to report. As for SPRL being real or a sham, if the stock rebounds it will have been real, if it continues to slide with continued issuance of hundreds of millions of shares (not just several million), then it will have been a sham. Gut check time fellas.

Play Episode

17min

Proactive - Interviews for investors

Oriole Resources wraps up pivotal 2024, targets major gold milestones in 2025

Oriole Resources PLC (AIM:ORR) CEO Martin Rosser and CFO Bob Smeeton take Proactive's Stephen Gunnion through the company’s latest full-year results and upcoming milestones across its key exploration projects. Rosser highlighted a pivotal year for the company’s Bibemi and Mbe gold projects in Cameroon. At Bibemi, a recently completed phase five drilling campaign is feeding into a revised Mineral Resource Estimate (MRE), expected this quarter. “We believe there's very good potential to not just increase the amount of gold, but also improve the category of the resource,” said Rosser. The company is also advancing an exploitation license application for the project. At Mbe, maiden drilling continues, following trenching results that indicated strong mineralisation. “We think Mbe South has significant potential to host a substantial gold deposit,” Rosser added. Smeeton detailed a £2 million reduction in operating loss and financial support from BCM International. “Since year-end, BCM have given us $1.1 million, largely replenishing CapEx,” Smeeton noted. He also confirmed progress on a joint venture agreement with Managem at the Senala project in Senegal. Rosser pointed to potential sector-wide revaluations driven by high gold prices and possible M&A activity. “Oriole’s shares are significantly undervalued,” he said. For more updates from Oriole Resources and other mining sector interviews, give this video a like, subscribe to Proactive’s YouTube channel, and enable notifications so you don’t miss future content. #OrioleResources #GoldExploration #CameroonMining #MbeProject #BibemiGold #JuniorMiners #MiningInvestment #MineralResourceEstimate #GoldPrice #MiningFinance #ProactiveInvestors #ManagemJV #SenalaProject #CameroonGold #ExplorationDrilling

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Proactive - Interviews for investors

Krakatoa’s antimony-gold find signals major upside

Krakatoa Resources Ltd chairman Colin Locke talked with Proactive about the company’s newly secured Zopkhito Project in Georgia, which he described as a major opportunity for investors. The project contains a JORC resource of 225,000 tonnes of high-grade antimony at 11% for 26,000 tonnes of metal, translating to a back-of-the-envelope valuation of approximately $1.30 billion based on current prices. Additionally, the project includes 7.1 million tonnes grading 3.7g/t gold for 815,000 ounces, estimated to be worth around $2.50 billion. Locke said, “This is touted to be the sixth biggest antimony project in the world.” The mineralisation is close to surface, and the company believes the resource has strong potential for expansion. He also highlighted the project’s additional gold content as another value driver. He attributed the company’s success in securing the project to its CEO and chief technical officer, Mark Major, whose experience in high-altitude exploration was a key factor for the local vendors. The project’s location in Georgia was described as highly investor-friendly, with a 15% corporate tax rate, no native title or land access complications, and strong support for foreign investment. Locke confirmed that a maiden drilling program is scheduled to begin shortly, with Major heading to Georgia next week to prepare. He emphasised the company’s past success with international projects and reassured investors of the team’s experience. In closing, he noted the company's current market capitalisation of just AUD 5 million, suggesting significant upside. 👉 For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future updates. #ProactiveInvestors #KrakatoaResources #ASX #gold #antimony

Followers	1
Posts	201
Boards Moderated	0
Alias Born	05/16/2006

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SPRL Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free